In recent years, scientists have discovered a new class of molecules which are able to exert control over the degradation of proteins within cells and achieve unique pharmacological effects. This exciting field of drug discovery has rapidly matured and the first candidate molecules are now being tested in clinical trials.
For the third conference of this series, we will bring together an exciting line up of academics and industrial speakers. They will share their cutting-edge science in the field of protein degradation covering a range of topics from understanding the underlying biological processes involved to delivering degraders into the clinic.
Call for posters
An abstract of maximum one A4 page or 300 words indicating title and authors should be sent to firstname.lastname@example.org by Friday 29 April with the subject line “Targeting protein degradation 3 – abstract submission”. Please use the template attached here.
This meeting aims to showcase recent innovations by scientists working in both academia and industry in this exciting and rapidly advancing field. It is targeted at academic and industrial scientists engaged in all aspects of research into protein degradation and those interested in broadening their knowledge in this field of drug discovery.
This event is being held back to back with "What's new in immunotherapies 2022".
Institute of Cancer Research
Alice Harnden is a medicinal chemist at the Institute of Cancer Research, London. She works on projects within the team of Professor Swen Hoelder seeking to discover new cancer treatments. She gain her undergraduate degree at Oxford University and completed her PhD at Durham University in 2019.
Andrew Leach is Head of Chemical Biology and Head of Industry Partnerships at the European Bioinformatics Institute (EBI). At the EBI he is responsible for a number of widely-used resources including ChEMBL, SureChEMBL, UniChem and ChEBI. His group is also involved in various international collaborations and consortia including Illuminating the Druggable Genome, Open Targets and EUbOPEN. His industry team works with the many commercial organisations and companies that make extensive use of the EBI's resources. He joined the EBI from GlaxoSmithKline, where over more than 20 years he was involved in the development and application of new platform capabilities for drug discovery in areas including computational chemistry and cheminformatics, fragment-based drug discovery, cardiovascular safety, proteomics and biological mass spectrometry. He also contributed to therapeutic projects and led GSK’s early Discovery portfolios against protease, ion channel and epigenetic targets.
University of Leicester
James Hodgkinson is a lecturer in Organic Chemistry and Chemical Biology at the Leicester Institute of Structural and Chemical Biology (LISCB) and School of Chemistry, University of Leicester. James completed his undergraduate degree in Chemistry at Queens University Belfast with a year in industry at GlaxoSmithKline and went on to complete his doctoral studies under the joint supervision of Professor David Spring (Department of Chemistry) and Dr Martin Welch (Department of Biochemistry), University of Cambridge. After a Junior Research Fellowship at Trinity College, Cambridge James was appointed to Lecturer at the University of Leicester in 2016. His current research interests are in the design and synthesis of heterobifunctional molecules to modulate Class-I Histone Deacetylase (HDAC) enzymes implicated in haematological cancers and other diseases, as well as chemical probes to aid structural studies of the protein-protein interactions within Class-I HDAC corepressor complexes.
Oskar leads our efforts in medicinal chemistry at Celeris Therapeutics. He works closely with our technology group to develop computation methods for the design of proximity-inducing compounds (PIC™) and validates PICs ex silico. Oskar holds a DPhil in organic chemistry from the University of Oxford, UK. Under the supervision of Prof. Donohoe, he worked on the total synthesis of marine furanocembranoidal natural products. At Hoffmann-La Roche in Basel, Switzerland, he worked in the department of small molecule process development. At the Ferrier Research Institute in Wellington, New Zealand, Oskar designed and synthesized enzyme inhibitors as a visiting researcher.
14/15 Belgrave Square
Tel: +44 (0)20 7598 1561
|Before early bird - ends 26 April 2022
SCI Member - £145
Non-member - £220
Student member - £65
|After early bird
SCI Member - £195
Non-member - £270
Student member - £85
There is a 10 percent reduction on the registration fee if you register for the What's new in immunotherapies event in addition to this meeting for SCI members and non-members.
Once you have registered for this event, please email email@example.com for a voucher code.
All registrations will automatically receive a confirmation within 24 hours of registering for the event. Should you not receive written confirmation of your booking, please email firstname.lastname@example.org.
Sign up as an Event Member to join this event. SCI Full or Student Members receive discounts on event registrations
SCI Members attending this meeting are able to claim CPD points.
Nicola Chessum, SCI / Boehringer Ingelheim
Martin Lowe, SCI / Exscientia
Jayshree Mistry, SCI
Jamie Scott, SCI / AstraZeneca
For further information and prices, please email email@example.com.